Safety evaluation of a short-term infusion of ramucirumab for GI tract cancer patients

Safety evaluation of a short-term infusion of ramucirumab for GI tract cancer patients - Safety evaluation of a short-term infusion of ramucirumab

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000029318

Enrollment

Registered

2017-09-28

Start date

2017-09-28

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric and colorectal cancer

Interventions

To administer ramucirumab in a short period of time

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Gastric or colorectal cancer patients who had undergone ramucirumab and are supposed to continue ramucirumab treatment

Exclusion criteria

Exclusion criteria: 1. Severe respiratory or cardiovascular diseases 2. Need for dose reduction of ramucirumab 3. Past history of infusion related reaction (grade3 or more) due to chemotherapeutic agents 4. Past history of infusion related reaction (any grade) due to ramucirumab 5. Daily use of antiallergic agents or steroids due to allergic diseases 6. Inadequate conditions, as diagnoses by the primary physician

Design outcomes

Primary

Measure	Time frame
Incidence of infusion related reaction (any grade) at the first short-term infusion	—

Secondary

Measure	Time frame
Incidence of infusion related reaction (any grade) at any time Incidence of adverse events (grade3 or more) except for infusion related reaction Duration of ramucirumab treatment	—

Countries

Japan

Contacts

Public ContactSeiichiro Mitani

Aichi Cancer Center Hospital the Department of Clinical Oncology

smitani@aichi-cc.jp052-762-6111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026